Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)

Asterias Biotherapeutics (AST) Set to Open Higher by 50% Following Positive Outcome from Safety Review Committee for AST-VAC2

July 11, 2018 7:26 AM EDT

Asterias Biotherapeutics (NYSE: AST) Set to Open Higher by 50% Following Positive Outcome from Safety Review Committee for AST-VAC2

... More